Biofrontera (BFRI) Finished Goods (2024 - 2025)

Biofrontera (BFRI) recorded quarterly Finished Goods of $1.4 million in Q4 2025, down 78.54% quarter-over-quarter from $6.6 million in Q4 2024, and down 78.54% on a YoY basis from $6.6 million in Q4 2024.

Biofrontera (BFRI) Finished Goods (2024 - 2025) Analysis & Trends

Biofrontera's Finished Goods history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2025.

  • In Q4 2025, Finished Goods fell 78.54% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (down 78.54% YoY), while the FY2025 annual figure was $1.4 million, down 78.54% from the prior year.
  • Finished Goods was $1.4 million for Q4 2025 at Biofrontera, down from $6.6 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $6.6 million in Q4 2024 to a low of $1.4 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Biofrontera 8.65 Mn 2.24 Mn 14.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.43 Mn
Dec 31, 2024 6.65 Mn